Category Press Releases

MEDIPAL and JCR Partner on Global Licensing for GM2 Therapy JR-479

MEDIPAL Holdings and JCR Pharmaceuticals Expand Rare Disease Collaboration with Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Investigational Therapy for GM2 Gangliosidosis In a significant advancement for patients and families affected by ultra-rare lysosomal storage disorders, MEDIPAL…

Read MoreMEDIPAL and JCR Partner on Global Licensing for GM2 Therapy JR-479

Neurotech Welcomes Dr. Peter J. McDonnell to Its Board of Directors

Neurotech Pharmaceuticals Strengthens Leadership with Appointment of Dr. Peter J. McDonnell to Board of Directors Neurotech Pharmaceuticals, Inc., a privately held biotechnology company pioneering transformative therapies for chronic eye diseases, today announced the appointment of Peter J. McDonnell, M.D., a…

Read MoreNeurotech Welcomes Dr. Peter J. McDonnell to Its Board of Directors

Enlaza and Vertex Partner on War-Lock Conjugates and T-Cell Engagers

Enlaza Therapeutics and Vertex Pharmaceuticals Forge Multi-Billion-Dollar Collaboration to Advance Next-Generation Covalent Biologics in Autoimmune Diseases and Conditioning Therapies Enlaza Therapeutics (“Enlaza” or the “Company”), a pioneering biotechnology firm and the first company to build a dedicated covalent biologics platform,…

Read MoreEnlaza and Vertex Partner on War-Lock Conjugates and T-Cell Engagers

Daiichi Sankyo Begins Development of Oral Triple Combo Lipid-Lowering Tablets for LDL-C Management

Daiichi Sankyo Advances Cardiovascular Care with Development of Oral Triple Combination Lipid-Lowering Tablets A New Chapter in Cholesterol Management Daiichi Sankyo Europe has unveiled an ambitious new initiative: the development of innovative oral triple combination tablets designed to help patients…

Read MoreDaiichi Sankyo Begins Development of Oral Triple Combo Lipid-Lowering Tablets for LDL-C Management
Xeris

Xeris Secures Orange Book Listing for U.S. Patent on Recorlev®XerisXeris Secures Orange Book Listing for U.S. Patent on Recorlev®

Xeris Biopharma Strengthens Long-Term Market Position with Orange Book Listing of New U.S. Patent for Recorlev® Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a rapidly expanding biopharmaceutical company focused on developing and commercializing innovative treatments to address complex and underserved medical…

Read MoreXeris Secures Orange Book Listing for U.S. Patent on Recorlev®XerisXeris Secures Orange Book Listing for U.S. Patent on Recorlev®

BeOne Medicines Secures Up to $950 Million Through IMDELLTRA Royalty Deal

BeOne Medicines Strikes $950 Million Royalty Deal with Royalty Pharma for IMDELLTRA, Strengthening Oncology Strategy and Financial Flexibility BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology-focused biotechnology company, announced a significant financial and strategic transaction involving…

Read MoreBeOne Medicines Secures Up to $950 Million Through IMDELLTRA Royalty Deal

Quanterix Accelerator Lab Secures Prestigious New York State Clinical Laboratory Permit

Quanterix Accelerator Laboratory Secures New York State Clinical Laboratory Permit, Expanding Biomarker Research and Clinical Testing Capabilities Nationwide Quanterix Corporation (NASDAQ: QTRX), a biotechnology company recognized for revolutionizing precision medicine through its ultrasensitive biomarker detection platforms, today announced a major…

Read MoreQuanterix Accelerator Lab Secures Prestigious New York State Clinical Laboratory Permit